You've reached 25 mg Wegovy — here's what that actually means

The morning you start 25 mg feels ordinary, the background work got you here

Imagine it's a Tuesday. You've been on oral semaglutide for the better part of four months. The tablet routine is ingrained now: alarm goes off, tablet out of the blister pack, small glass of plain water, thirty minutes before coffee or breakfast. That habit is what gets you to 25 mg in good shape. The titration schedule (1.5 mg for at least a month, then 4 mg, then 9 mg, then 25 mg) exists precisely so your digestive system adjusts gradually rather than meeting the full dose all at once.

At 25 mg you're on the maximum licensed dose. That matters because the clinical evidence underpinning the MHRA's approval was built at this level. The OASIS 4 trial, which Novo Nordisk reported as part of the June 2026 approval, followed 307 adults with obesity or overweight plus at least one weight-related condition over 64 weeks. Average weight loss across all participants on the treatment reached around 13.6%, rising to roughly 17% among those who stayed fully adherent throughout, a distinction worth keeping clear. Wegovy's full evidence profile covers both the injection and tablet arms of the programme.

One quick check that takes under a minute: open your pill case and confirm the blister strip says 25 mg, not 9 mg. They look similar, and a mix-up at this stage would mean undershooting your maintenance dose without realising. Worth the three seconds every morning.

What 25 mg does differently from lower doses, and why the GI pattern shifts

Every dose step of oral semaglutide works through the same mechanism: the semaglutide molecule, carried across the stomach lining by an absorption enhancer called SNAC, activates GLP-1 receptors involved in appetite signalling and gastric emptying. At 25 mg, that signal is at its strongest. Appetite suppression is more pronounced. Gastric emptying slows further. For many people that translates into feeling full on noticeably less food than they were eating at 9 mg.

The trade-off is that gastrointestinal side effects (nausea, loose stools, constipation, upper stomach discomfort) can resurface when you step up, just as they may have done at 4 mg and 9 mg. In the OASIS 4 trial, around 74% of participants on oral semaglutide reported GI effects at some point, versus 42% on placebo; most were mild to moderate and settled over time. The NHS medicines guidance for semaglutide describes the typical side-effect profile in detail. If nausea at 25 mg is significant, your prescriber may recommend staying at the lower dose for longer rather than pushing through, that's a clinical conversation, not a decision to make alone.

People sometimes ask whether they can split the 25 mg tablet to reduce side effects. The short answer from the SmPC is no: the tablet should be swallowed whole. The SNAC absorption mechanism depends on the formulation staying intact. Your prescriber and the patient information leaflet are the right reference for managing any tolerability issues at this dose.

Who reaches 25 mg, and when it might not be the right endpoint for everyone

The titration path to 25 mg assumes tolerability at every preceding step. Not everyone gets there, and that's not a failure. Some patients find a meaningful response at 9 mg and, in consultation with their prescriber, remain there. If you want to understand how each Wegovy mg step fits into the overall schedule, the key principle is that the goal is the lowest effective dose that produces meaningful weight loss with acceptable tolerability. You can also find detail on how Wegovy's full dose range works across the programme.

Eligibility for the Wegovy tablet (at any dose) follows the MHRA-licensed criteria: adults with a BMI of 30 or above, or between 27 and 29.9 with at least one weight-related condition such as high blood pressure, dyslipidaemia or type 2 diabetes, alongside a reduced-calorie diet and increased physical activity. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE has not yet appraised oral semaglutide, so it is not currently available through the NHS, a private prescription is the route at launch.

The Wegovy tablet doesn't need refrigeration, which is a practical advantage for anyone who travels frequently or simply finds managing a cold-chain pen inconvenient. Room-temperature storage and a once-daily oral routine rather than a weekly injection change the day-to-day texture of treatment for some people. Whether that suits your situation is worth discussing with a prescriber. Those earlier in the titration process may find it helpful to read about how the Wegovy 1 mg starting point works before progressing through the schedule. For a broader overview of oral versus injection options, our treatment overview sets out what's available.

The cost of Wegovy treatment in the UK varies by dose and provider, the 25 mg maintenance dose sits at the higher end of the schedule, so it's worth understanding what a transparent private price includes before you commit to a service. Patients moving from the injection to the tablet, or transferring from another provider, should bring evidence of their current treatment and dose to any new clinical review, and those on the penultimate step can read about how the 2 mg Wegovy dose fits into the journey before stepping up. Our clinical team reviews every repeat order before it's dispensed, regardless of how long someone has been on treatment.